Development of a Physiologically Based Pharmacokinetic Model for Ethylene Glycol and Its Metabolite, Glycolic Acid, in Rats and Humans

An extensive database on the toxicity and modes of action of ethylene glycol (EG) has been developed over the past several decades. Although renal toxicity has long been recognized as a potential outcome, in recent years developmental toxicity, an effect observed only in rats and mice, has become th...

Full description

Saved in:
Bibliographic Details
Published in:Toxicological sciences 2005-05, Vol.85 (1), p.476-490
Main Authors: Corley, R. A., Bartels, M. J., Carney, E. W., Weitz, K. K., Soelberg, J. J., Gies, R. A., Thrall, K. D.
Format: Article
Language:English
Subjects:
Animals
Blood Proteins - metabolism
Dose-Response Relationship, Drug
ethylene glycol
Ethylene Glycol - blood
Ethylene Glycol - pharmacokinetics
Ethylene Glycol - urine
Female
Glycolates - blood
Glycolates - metabolism
Glycolates - urine
glycolic acid
Humans
Male
Metabolic Clearance Rate
Models, Biological
PBPK modeling
Rats
Rats, Sprague-Dawley
Risk Assessment
Species Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An extensive database on the toxicity and modes of action of ethylene glycol (EG) has been developed over the past several decades. Although renal toxicity has long been recognized as a potential outcome, in recent years developmental toxicity, an effect observed only in rats and mice, has become the subject of extensive research and regulatory reviews to establish guidelines for human exposures. The developmental toxicity of EG has been attributed to the intermediate metabolite, glycolic acid (GA), which can become a major metabolite when EG is administered to rats and mice at high doses and dose rates. Therefore, a physiologically based pharmacokinetic (PBPK) model was developed to integrate the extensive mode of action and pharmacokinetic data on EG and GA for use in developmental risk assessments. The resulting PBPK model includes inhalation, oral, dermal, intravenous, and subcutaneous routes of administration. Metabolism of EG and GA were described in the liver with elimination via the kidneys. Metabolic rate constants and partition coefficients for EG and GA were estimated from in vitro studies. Other biochemical constants were optimized from appropriate in vivo pharmacokinetic studies. Several controlled rat and human metabolism studies were used to validate the resulting PBPK model. When internal dose surrogates were compared in rats and humans over a broad range of exposures, it was concluded that humans are unlikely to achieve blood levels of GA that have been associated with developmental toxicity in rats following occupational or environmental exposures.
ISSN:1096-6080
1096-0929
DOI:10.1093/toxsci/kfi119